SPI Pharmaceuticals Inc.: The Costa Mesa drug...
SPI Pharmaceuticals Inc.: The Costa Mesa drug company reported third-quarter net income of $3.4 million, up 21% from $2.8 million a year earlier. Sales for the period ended Aug. 31 rose 8% to $31.4 million from $29 million. Nine-month net income totaled $10.2 million, 11% higher than the $9.2 million posted in the year-earlier period. Sales rose 9% to $97.1 million from $88.9 million.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
